Lenalidomide - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Lenalidomide market size in 2026 is estimated at USD 16.03 billion, growing from 2025 value of USD 15.21 billion with 2031 projections showing USD 20.85 billion, growing at 5.39% CAGR over 2026-2031. This report is Segmented by Application (Multiple Myeloma, Mantle Cell Lymphoma, and More), Dosage Strength (2. 5 Mg, 5 Mg, 10 Mg, 15 Mg, 25 Mg, and Others), Age Group (Adults, Geriatric, and More), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and More), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and More). The Market and Forecasts are Provided in Terms of Value (USD).

Global Lenalidomide Market Trends and Insights

Rising Global Incidence of Multiple Myeloma & Related Blood Cancers

Incidence rates for plasma-cell malignancies continue to climb in aging populations, anchoring sustained demand for lenalidomide-based therapy. In North America and Europe, guideline updates position continuous maintenance as a cornerstone of early-line management, leading to prolonged treatment durations. Epidemiologic expansion aligns with rising geriatric cohorts, many of whom remain on therapy beyond 24 months when tolerated. This demographic pattern supports consistent volume growth across mature reimbursement systems and heightens the strategic importance of dose optimization for frail patients.

Expanding Label Indications, Including Lymphomas and Maintenance Therapy

Regulatory authorities have broadened lenalidomide use into mantle cell lymphoma and certain lymphomas that relapse after anti-CD20 therapy. The United States Food and Drug Administration cleared isatuximab with lenalidomide for transplant-ineligible multiple myeloma in 2024, reaffirming its versatility in combination protocols. Such approvals diversify revenue streams and reduce reliance on a single disease state.

Severe Side-Effects and Stringent REMS Compliance Burden

Lenalidomide carries teratogenic risk that mandates a Risk Evaluation and Mitigation Strategy. Oncologists must coordinate pregnancy testing, counseling, and restricted dispensing, which adds workflow complexity. Peer-reviewed data show that 31.9% of maintenance patients discontinue within the first year owing to toxicities such as cytopenias and fatigue. Community clinics with limited staffing experience the greatest administrative strain, tempering uptake despite proven efficacy.

Other drivers and restraints analyzed in the detailed report include:

• Availability of Generics Driving Affordability and Wider Access
• Integration into Standard Triplet/Quadruplet Treatment Regimens
• Next-Generation CELMoDs and Bispecifics Cannibalising Demand

Segment Analysis

Multiple myeloma accounted for 59.72% of 2025 revenue and remains the anchor of the lenalidomide market. Regulatory endorsement of quadruplet induction ensures continued frontline use, while maintenance protocols secure extended dosing. Mantle cell lymphoma, though smaller in absolute dollars, posts a 5.93% CAGR through 2031 as combination studies with rituximab and ibrutinib advance into clinical guidelines. Continued trial activity in chronic lymphocytic leukemia could further diversify indications if safety remains acceptable.

Broader application drives incremental volume but also heightens competitive complexity, as biologic agents increasingly aim for the same patient pools. Even so, physicians favor lenalidomide for del(5q) myelodysplastic syndromes, reinforced by major hematologic response in real-world registries. These application trends underscore why the lenalidomide market size attached to oncology indications remains resilient, even while generics pressure average selling prices.

The 25 mg capsule remained the most prescribed strength in 2025 with 34.83% of revenue. High-dose induction remains standard, yet real-world practice increasingly shifts to 15 mg, 10 mg, or 5 mg maintenance to balance efficacy and tolerability. The 2.5 mg format posts a 6.12% CAGR as clinicians adopt micro-dosing for frail or renal-impaired patients. Evidence from multinational trials supports modified dosing without compromising response, fueling demand for dose-diverse generics.

Manufacturers compete on capsule assortment breadth and packaging efficiencies. Once generic supply constraints ease, competitive bids for public tenders are expected to widen access to every dose tier. As a result, the lenalidomide market size tied to low-strength capsules should expand faster than the top-line market.

Complete Report Scope:

• By Application
  • Multiple Myeloma
  • Myelodysplastic Syndromes (MDS)
  • Mantle Cell Lymphoma
  • Follicular & Marginal-Zone Lymphoma
  • Chronic Lymphocytic Leukemia
  • Other Applications
• By Dosage Strength
  • 2.5 mg
  • 5 mg
  • 10 mg
  • 15 mg
  • 25 mg
  • Others
• By Age Group
  • Adults
  • Geriatric
  • Pediatric
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America commanded 40.35% of 2025 revenue. Comprehensive insurance coverage and early adoption of quadruplet induction regimens underpin market leadership. However, 2025 Medicare Part D formulary exclusions for Revlimid create headwinds that may accelerate the switch to less expensive generics for eligible seniors. Price renegotiations after 2026 are expected to unlock stronger volume in value-based payment models.

Asia-Pacific delivers the highest growth at 6.28% CAGR to 2031. China’s 2024 approval of first-line lenalidomide regimens and provincial reimbursement will add thousands of new patients annually. In India, vertically integrated API production supports stable supply and competitive tender pricing in public hospitals. Japan’s super-aged society and adoption of oral proteasome inhibitor-lenalidomide combinations also bolster demand, offsetting sporadic supply constraints during global API shortages.

Europe remains a mid-single-digit growth territory. Generic launches across the region in 2022 triggered rapid conversion from branded to biosimilar-equivalent offerings GaBI. Centralized procurement in markets such as the United Kingdom accelerated savings by switching patients to generics while maintaining clinical outcomes. Nonetheless, pharmacists monitor potential API sourcing risks as new Chinese export controls tighten supply audits.

List of Companies Covered in this Report:

• Bristol-Myers Squibb
• Teva Pharmaceutical Industries
• Dr. Reddy’s Laboratories
• Cipla
• Sandoz Group
• NATCO Pharma
• Hetero Healthcare
• Amneal Pharmaceuticals
• Apotex
• Reliance Life Sciences
• Synthon
• Deva Holding
• Delphis Pharma
• Accord Healthcare
• Sun Pharmaceuticals Industries
• Viatris
• Lupin
• Zydus Lifesciences
• Glenmark Pharmaceuticals
• Intas Pharmaceuticals

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support